

AD\_\_\_\_\_

AWARD NUMBER: W81XWH-04-1-0920

TITLE: Preclinical Evaluation of Serine/Threonine Kinase Inhibitors Against Prostate Cancer Metastases

PRINCIPAL INVESTIGATOR: Theresa Guise, M.D.

CONTRACTING ORGANIZATION: University of Virginia  
Charlottesville, Virginia 22904

REPORT DATE: November 2005

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                         |                                 |                                             |                                                                  |                                                   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|---------------------------------|---------------------------------------------|------------------------------------------------------------------|---------------------------------------------------|
| <b>REPORT DOCUMENTATION PAGE</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                         |                                 |                                             | <i>Form Approved</i><br><b>OMB No. 0704-0188</b>                 |                                                   |
| Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b> |                         |                                 |                                             |                                                                  |                                                   |
| <b>1. REPORT DATE (DD-MM-YYYY)</b><br>01-11-2005                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                         | <b>2. REPORT TYPE</b><br>Annual |                                             | <b>3. DATES COVERED (From - To)</b><br>15 Oct 2004 – 14 Oct 2005 |                                                   |
| <b>4. TITLE AND SUBTITLE</b><br><br>Preclinical Evaluation of Serine/Threonine Kinase Inhibitors Against Prostate Cancer Metastases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                         |                                 |                                             | <b>5a. CONTRACT NUMBER</b>                                       |                                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                         |                                 |                                             | <b>5b. GRANT NUMBER</b><br>W81XWH-04-1-0920                      |                                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                         |                                 |                                             | <b>5c. PROGRAM ELEMENT NUMBER</b>                                |                                                   |
| <b>6. AUTHOR(S)</b><br><br>Theresa Guise, M.D.<br><br>E-Mail: <a href="mailto:tag4n@virginia.edu">tag4n@virginia.edu</a>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                         |                                 |                                             | <b>5d. PROJECT NUMBER</b>                                        |                                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                         |                                 |                                             | <b>5e. TASK NUMBER</b>                                           |                                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                         |                                 |                                             | <b>5f. WORK UNIT NUMBER</b>                                      |                                                   |
| <b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b><br><br>University of Virginia<br>Charlottesville, Virginia 22904                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                         |                                 |                                             | <b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>                  |                                                   |
| <b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b><br>U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                         |                                 |                                             | <b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>                          |                                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                         |                                 |                                             | <b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>                    |                                                   |
| <b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b><br>Approved for Public Release; Distribution Unlimited                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                         |                                 |                                             |                                                                  |                                                   |
| <b>13. SUPPLEMENTARY NOTES</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                         |                                 |                                             |                                                                  |                                                   |
| <b>14. ABSTRACT</b><br><br>A central tenet of the field of bone metastases is that the bone microenvironment supplies factors, such as TGF-beta, stimulating prostate cancer cell signaling and altering their phenotype. TGF-beta signaling in cancer is however complex and can lead to the activation of numerous genes. We have identified many of these genes by microarray analysis and have validated the gene reported here. Of these, PMEPA1 as the most highly upregulated gene. We have cloned the PMEPA1 promoter and full-length gene and have begun promoter analysis of the TGFβbetaresponse element. We are in the process of overexpressing PMEPA1 in prostate cancer lines. In vivo experiments are in progress to determine the effect of a TGFbeta RI kinase inhibitor, SD-208, on the development and progression of prostate cancer metastases to bone due to PC-3, LuCAP and C42B prostate cancers.                                |                         |                                 |                                             |                                                                  |                                                   |
| <b>15. SUBJECT TERMS</b><br>Bone metastases, prostate cancer, TGF-beta, PMEPA1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                         |                                 |                                             |                                                                  |                                                   |
| <b>16. SECURITY CLASSIFICATION OF:</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                         |                                 | <b>17. LIMITATION OF ABSTRACT</b><br><br>UU | <b>18. NUMBER OF PAGES</b><br><br>28                             | <b>19a. NAME OF RESPONSIBLE PERSON</b><br>USAMRMC |
| <b>a. REPORT</b><br>U                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | <b>b. ABSTRACT</b><br>U | <b>c. THIS PAGE</b><br>U        |                                             |                                                                  | <b>19b. TELEPHONE NUMBER (include area code)</b>  |

## **Table of Contents**

|                     |         |
|---------------------|---------|
| Introduction        | Page 4  |
| Body                | Page 4  |
| Hypotheses          | Page 5  |
| Specific Aims       | Page 5  |
| Results             | Page 7  |
| Reportable Outcomes | Page 17 |
| Conclusions         | Page 19 |
| References          | Page 20 |

## Introduction

Prostate cancer has a propensity to grow in the skeleton and cause significant morbidity. Once housed in bone, prostate cancer is incurable. Bone is a rich storehouse of growth factors, which stimulate signaling in metastatic cancer cells. Bone-derived TGF $\beta$  increases tumor secretion of factors that activate bone remodeling, fueling a vicious cycle, which drives the growth and survival of prostate bone metastases. In prostate cancer cells, TGF $\beta$  signals through two receptor subunits and, further downstream, p38 MAP kinase. Hypothesis: *TGF $\beta$  mediates prostate cancer metastases to bone via p38 MAP kinase pathway. TGF $\beta$  and/or p38MAP kinase signaling inhibitors will reduce the development and progression of prostate cancer bone metastases to bone.* Two orally active inhibitors of these serine/threonine kinases will be tested in an animal model of prostate cancer bone metastases. We propose three Specific Aims. Aim 1: To test a TGF $\beta$ RI kinase inhibitor and a p38 MAPK inhibitor against three human prostate cancer models of skeletal metastasis in mice. Aim 2: To determine the molecular targets of these inhibitors in prostate cancer cells *in vitro* and test their impact on tumor growth and bone metastases *in vivo*. Aim 3: To test the efficacy of combined TGF $\beta$ RI and p38 MAP kinase inhibitors against three prostate cancer models *in vivo*.

## Body

**BACKGROUND.** The skeleton is a major site of metastasis by advanced prostate cancer. Last year 220,900 cases of prostate cancer were diagnosed in the United States, where it is now the most commonly diagnosed cancer and the second most common cause of cancer mortality in men, with 28,900 deaths (Crawford, 2003). One fourth of diagnosed patients will die from the disease, the majority of them with metastases to the skeleton. Once cancer becomes housed in bone, it is incurable. The average survival from time of diagnosis of skeletal metastases in prostate cancer patients is 40 months. When prostate tumor cells metastasize to the skeleton, the most common response is osteoblastic: characterized by net formation of disorganized new bone, which results in fractures, severe and intractable bone pain, and nerve compression. Metastasis to bone thus causes prolonged, serious morbidity for many prostate cancer patients. Treatment to prevent or halt the progression of bone metastases (Reddi et al, 2003; O’Keefe and Guise, 2003). would increase survival and improve quality of life for men with prostate cancer

***Transforming growth factor- $\beta$  in cancer is a two-edged sword.*** TGF $\beta$  is a growth inhibitor and a tumor suppressor at early stages of the oncogenic cascade. However, advanced cancers often lose the growth inhibition by TGF $\beta$  but continue to respond to the factor. The net effect is that TGF $\beta$  is a metastasis enhancer for advanced cancers. Since bone is a major source of active TGF $\beta$ , the factor plays a crucial role in the vicious cycle of bone metastases. Blockade of the TGF $\beta$  pathway effectively decreases metastases in several animal models (Yin et al, 1996; Muraoka et al, 2002; Yang et al, 2002).

***Transforming growth factor- $\beta$  in bone*** is released from mineralized matrix in active form by osteoclastic resorption (Dallas et al, 2002), which is very prominent in prostate cancer metastases. TGF $\beta$  acts on tumor cells to increase the secretion of factors that inappropriately stimulate bone cells (Chirgwin & Guise, 2003a,b). The interactions

between bone and cancer constitute a vicious cycle, which enhances skeletal metastases (Mundy, 2002). Extensive data show that TGF $\beta$  is a major bone-derived factor responsible for driving the vicious cycle of cancer metastases in bone. TGF $\beta$  increases tumor secretion of factors such as endothelin-1, IL-6, IL-11, PTHrP, and VEGF. These factors stimulate both osteoblastic synthesis of disorganized new bone and osteolytic destruction of the skeleton adjacent to tumor cells. The cellular and molecular components of the vicious cycle between tumor and bone offer opportunities for therapeutic intervention to decrease skeletal metastases (Coleman, 2002; Guise & Chirgwin, 2003a). TGF $\beta$  in particular is an important target for intervention against prostate cancer skeletal metastases.

***Therapy to block TGF $\beta$  signaling in bone metastases.*** Previous work has demonstrated the effectiveness of TGF-beta inhibition to decrease metastases, but these experiments have used protein-based treatment or ex vivo manipulations of the tumor cells (Yin et al, 1996; Muraoka et al, 2002; Yang et al, 2002). Orally active small-molecule inhibitors of the TGF $\beta$  pathway would be much more practical. This proposal will test two inhibitors of serine/threonine kinases. The first directly targets the TGF $\beta$  receptor kinase. The second targets p38 MAP kinase, which is a major downstream effector of TGF $\beta$  signaling in cancer cells. Both targets are serine/threonine kinases. Our preliminary data show that inhibition of TGF $\beta$  signaling is effective in an animal model of cancer bone metastases. The work proposed will test the two serine/threonine kinases inhibitors in animal models of human prostate cancer in bone: one in which the response is osteolytic, two others in which it is osteoblastic. The experiments proposed will rapidly provide the preclinical data necessary for these two drugs to be placed in clinical trials for prostate cancer bone metastases.

***Hypotheses:*** 1) TGF $\beta$  mediates prostate cancer metastases to bone via p38 MAP kinase. Specific serine/threonine kinase small-molecule inhibitors of the type I TGF $\beta$  receptor kinase and of p38 MAP kinase will reduce the development and progression of prostate cancer metastases to bone, due to either osteoblastic or osteolytic diseases. 2) Orally active inhibitors of these serine/threonine kinases will be effective in animal models of prostate cancer bone metastases to decrease metastases and tumor burden and to increase survival. 3) The two drugs may be more effective in combination than singly, if p38 MAP kinase also mediates TGF $\beta$ -independent metastatic functions. 4) Specific targets of TGF $\beta$  signaling in prostate cancer cells contribute directly to the bone phenotype of metastases. One such factor may be the type I membrane protein PMEPA1, which is regulated by TGF $\beta$  and expressed by prostate cancers. 5) Expression of PMEPA1 on the surface of cancer cells will increase the development and progression of prostate cancer metastases to bone.

***Specific Aim 1:*** To determine the effect of TGF $\beta$ RI kinase or p38 MAPK blockade separately against 3 human prostate cancer models of skeletal metastasis in mice (hypotheses 1 & 2).

***Results and Progress:*** This experiment is in progress with respect to the TGF $\beta$ RI kinase inhibitor. We are testing the effects of the TGF $\beta$ RI kinase, SD-208, on the development and progression of bone metastases due to PC-3 prostate cancer. This aim has taken

longer than originally planned because we had to determine long-term pharmacokinetics for drug delivery in the food. We have pharmacokinetic data that 50 and 100 mg/kg of SD-208 added to food result in drug levels that were effective in our mouse model of breast cancer metastases to bone. The p38MAPK inhibitor experiments have not been started as our pilot experiment showed that drug treatment appeared to be toxic for the mice: they developed fragile bones. However, we plan to test the p38MAPK inhibitor in PC-3 tumor-bearing mice in the next grant year, once we have established all the toxicities associated with this compound.

**Specific Aim 2:** To determine the molecular targets of the inhibitors in prostate cancer cells in vitro by gene array analysis (hypothesis 4). The role of an already-identified target of TGF $\beta$ , PMEPA1, will be tested in the animal models by overexpressing it in 2 prostate cancer cell lines (hypothesis 5).

*Results and Progress:* The majority of the work from year 1 has been performed on this aim. Gene array targets of TGF $\beta$  on PC-3 prostate cancer were validated by quantitative real-time PCR and are described below.

**Specific Aim 3:** To test the efficacy of combined T $\beta$ RI and p38 MAPK inhibitors against 3 prostate cancer models in vivo (hypothesis 3).

*Results and Progress:* This aim has not been started and is planned for the last year of the proposal.

## **Results:**

### **Validation of the micro-array experiment using qRT-PCR**

#### **Method**

PC-3 cells were grown in cell culture dishes until they reach near confluency and were starved for 24H in F12-K basal medium. The cell monolayer was rinsed twice with PBS and the cells were further cultured in F12-K medium containing or not containing TGF- $\beta$ 1 (5ng/mL) for different amount of time (0, 1, 2, 4, 8, 12, 24 and 48H).

The conditioned media were collected and supplemented with anti-proteases (aprotinin and leupeptin, 2 $\mu$ g/mL final concentration). The solutions were centrifuged (1,000g, 5min, 4°C) to remove cell debris and the supernatant were aliquoted and frozen at -80°C for further protein analysis.

The cell monolayers were rinsed with PBS and trypsinized (2mL Trypsine/EDTA, 3min, 37°C). Trypsinization was stopped by adding 8mL of ice-cold complete F12-K. Cells were centrifuged (800g, 5min, 4°C) and the pellets were washed twice in ice-cold PBS. The total RNA was extracted from cell pellets (RNeasy lipid tissue kit, Qiagen) and treated with DNase I to avoid DNA contamination (RNase free DNase set, Qiagen). RNA was used for cDNA synthesis (SuperScript™ II reverse transcriptase kit, Invitrogen). The cDNA were used as template in a quantitative real-time PCR (QuantiTect SYBR green PCR kit, Qiagen) using BioRad MyiQ thermocycler (annealing temperature 58°C).


Similar real-time PCR were run with the cDNA obtained from the PC-3 cells, treated or not treated with TGF- $\beta$  (5ng/mL, 48H) and used for the micro-array experiment.

Primer used for the qRT-PCRs were chosen for genes selected from the micro-array analysis (PMEPA1, MMP-13, ADAM19, THBSP1, PTHrP, CTGF, VEGF) or from the literature (IL-6, IL-11, Cyr61, VEGF121, VEGF165). Endogenous genes human Rpl32 (ribosomal protein L32) and HPRT (hypoxanthine phosphoribosyltransferase 1) were used to normalized the results. Primers were designed using Primer3 ([http://frodo.wi.mit.edu/cgi-bin/primer3/primer3\\_www.cgi](http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi)).

All conditions were run as a triplicate. The real-time threshold values (Ct) were analyzed using the  $\Delta\Delta C_t$  method, where the amount of mRNA is calculated as  $2^{-\Delta\Delta C_t}$ . The untreated cells at the same time-point were used as a calibrator at 1.0. L32 and HPRT were both used as endogenous genes and gave similar results. Data shown were calculated using L32 and values represent the means  $\pm$  SD of the triplicate. Statistical significance was calculated using an unpaired, one-tailed Student *t* test (\*,  $P < 0.05$  when compared to the untreated cells at 0H).

| Gene        | Forward (5'→3')                     | Reverse (5'→3')                   |
|-------------|-------------------------------------|-----------------------------------|
| L32         | CAG GGT TCG TAG AAG ATT CAA GGG     | CTT GGA GGA AAC ATT GTG AGC GAT C |
| HPRT        | CCT CCG CCT CCT CCT CTG             | CCT GGT TCA TCA CTA CTA ATC ACG   |
| PTHrP       | ACG GCG ACG ATT CTT CCT TC          | CCA CCT TGT TAG TTT CCT GAG TTA   |
| CTGF        | GCT ACC ACA TTT CCT ACC TAG AAA TCA | GAC AGT CCG TCA AAA CAG ATT GTT   |
| Cyr61       | CCT CGG CTG GTC AAA GTT AC          | AGG CTC CAT TCC AAA AAC AG        |
| PMEPA1      | AGA ACA CTC CGC GCT TCT TA          | AGA ACA CTC CGC GCT TCT TA        |
| MMP-13      | AAC ATC CAA AAA CGC CAG AC          | GGA AGT TCT GGC CAA AAT GA        |
| VEGF (all)  | AAG GAG GAG GGC AGA ATC AT          | CAC ACA GGA TGG CTT GAA GA        |
| VEGF165     | GAA AAT CCC TGT GGG CCT TG          | GTC ACA TCT GCA AGT ACG TTC G     |
| VEGF121     | CCC ACT GAG GAG TCC AAC AT          | TGC GCT TGT CAC ATT TTT CTT G     |
| IL-6        | GAA AGC AGC AAA GAG GCA CT          | TTT CAC CAG GCA AGT CTC CT        |
| IL-11       | TGA AGA CTC GGC TGT GAC C           | CCT CAC GGA AGG ACT GTC TC        |
| ADAM19      | CAG TCA GGT GGT GGA ATG TG          | ATT GCA GCA GGG GTT GTT AC        |
| THBS1-A     | CAG TCA GGT GGT GGA ATG TG          | ATT GCA GCA GGG GTT GTT AC        |
| THBS1-B     | TTT CTC AGA ACA GCG GGA CT          | TGT TGA TCA CCT TTC GCT TG        |
| PMEPA1 var1 | AAA CCC GAT CTC CTT GGA CT          | AGC CTC TGC CGC TAG CTT           |
| PMEPA1 var2 | AAA CCA GGC AAT GGC GGA G           | GAC CGT GCA GAC AGC TTG TA        |
| PMEPA1 var3 | AAA CCA GCG GAG CTG GAG T           | GAC CGT GCA GAC AGC TTG TA        |
| PMEPA1 var4 | CAA GCC TCC TGG TCT TTC TG          | GCT AGA CCA GAG CGA ATT CA        |


## Results



Fold change measured by the micro-array:  $\times 23.15$  vs untreated cells.

PMEPA1 expression is significantly increased, rapidly after TGF- $\beta$  treatment (within 1H) and reaches a maximum at 24H. Cycloheximide will be added to the medium to determine whether the induction is direct.





### PMEPA1 Variants

Four different mRNA variants result from the transcription of the PMEPA1 gene, after alternative splicing. These variants code for 3 different isoform of the protein which functions are unknown. Real-time PCR was performed on the cDNA of PC-3 cells treated or not treated with TGF- $\beta$  (5ng/mL) for 24H, using pairs of primers specific for the different variants.


These results indicate that variant 1, 2 and 4 are expressed in PC-3 cells (Shown below). The expression of these mRNA is increased by TGF- $\beta$ . No PCR product could be detected for the variant 3, using 2 different pairs of primers, suggesting that it is not produced. The  $\Delta C_t$  values of the different variant indicate that:

- 1) in untreated cells: variant 4 > variant 2 > variant 1
- 2) in TGF- $\beta$  treated cells: variant 2 > variant 4 > variant 1


The membrane anchored protein may be predominant form in TGF- $\beta$  treated cells. But, once again, these results must be further confirmed using amplification products to assess the reaction efficiency and to realize a standard curve.

We have cloned the promoter for PMEPA1 and have started analysis of TGF $\beta$  regulation of this promoter. We are also in the process of knock-down or overexpression of PMEPA1 in PC-3 prostate cancer.

Link to PubMed Gene: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene&cmd=Retrieve&dopt=full\\_report&list\\_uids=56937](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene&cmd=Retrieve&dopt=full_report&list_uids=56937).




#### MMP-13 (collagenase 3)



Fold change measured by the micro-array:  $\times 3.40$  vs untreated cells.

TGF- $\beta$  induces an increase of MMP-13 transcription after 12H and that reach a maximum at 24-48H. This late activation suggests that it is an indirect process due to another gene activated by TGF- $\beta$ . This will be determined using cycloheximide analysis. The role of MMPs in bone metastasis is known to be important (Kang et al, 2003; Lynch et al, 2005) and should prove to be a worthy target for TGF- $\beta$  inhibition.


#### ADAM19 (A Disintegrin And Metalloprotease Domain 19 or meltrin $\beta$ )



Fold change measured by the micro-array:  $\times 2.73$  vs untreated cells.

Four hours after the beginning of TGF- $\beta$  treatment, ADAM19 transcription is stably upregulated, so it may then be a direct target of the TGF- $\beta$  pathway. Little is known about the regulation of ADAM19 by TGF- $\beta$ . Two different forms of ADAM19 mRNA result from alternative splicing. Some ADAM proteins (i.e., ADAM12 also known as meltrin  $\alpha$ , ADAM17 also known as TACE) have been shown to be associated with osteoclastogenesis. Some ADAM proteins are important for the TNF $\alpha$  shedding (Zheng *et al.* 2004. JBC. 279:42898) and can then release RANKL from the membrane, regulating osteoclastogenesis (Lum *et al.* 1999. JBC. 274:13613). Further study of the role of ADAM19 in the osteoclastogenesis due to the osteolytic PC-3 and to compare with osteoblastic prostate cancer cell lines (i.e. C4-2B) is justified by these studies.

Link to PubMed Gene: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene&cmd=Retrieve&dopt=full\\_report&list\\_uids=8728](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene&cmd=Retrieve&dopt=full_report&list_uids=8728)





Fold change measured by the micro-array:  $\times 3.81$  or  $\times 2.27$  (pending on the probe) vs untreated cells.

TSP1 transcription is quickly upregulated by TGF- $\beta$  during the first 12-24H. However it appeared on the melt curve of the PCR that with the primers THBSP1-A a second peak ( $t^{\circ}$  85°C) is appearing in the reaction after 48H (graph next page). This peak seems smaller in TGF- $\beta$  treated cell samples than in untreated samples. This peak correspond to an amplification product of  $\approx 250$ bp which should be sequenced. It may be possible that it is a splicing variant repressed by TGF- $\beta$ , however no alternative splicing has been detected so far for TSP1.

TSP1 is known as an activator of TGF- $\beta$  (from the latent to the active form; Crawford *et al.* 1998. Cell. 93:1159) and was characterized as an inhibitor of angiogenesis (Good *et al.* 1990. PNAS. 87:6624) or of metastasis (Volpert *et al.* 1998. PNAS. 95:6343). However breast or prostate tumors can become resistant to TSP1 anti-angiogenic properties (Filleur *et al.* 2001. Genes & Dev. 15:1373; Fontana *et al.* 2005. Int. J. Cancer. 116:686). It is possible that TGF- $\beta$  is involved in the acquisition of this resistance.


Link to PubMed Gene: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene&cmd=Retrieve&dopt=full\\_report&list\\_uids=7057](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene&cmd=Retrieve&dopt=full_report&list_uids=7057)



No changes detected by the micro-array.


IL-11 transcription is transiently increased by TGF- $\beta$  (maximum at 2H). A secondary activation may also occur, starting at 24H. TGF- $\beta$  control of IL-11 transcription has been very well studied in breast cancer cells (Kang *et al.* 2005. PNAS. 102:13909). They noticed an immediate gene response, peaking at 2H and gradually declining thereafter,

which is well correlated with our results. IL-11 is also known to be involved in osteoclastogenesis and in osteolytic breast cancer metastasis. The transient overexpression induced by TGF- $\beta$  explain that IL-11 was not pinpointed in the micro-array.



No changes detected by the micro-array.


TGF- $\beta$  induces a slight increase in Cyr61 transcription (maximum  $\times 1.70$ , at 8H). Cyr61 is known to be a target of TGF- $\beta$ , and Bartholin *et al.* (Cancer Letters 2006) fully described the effects of TGF- $\beta$  in this promoter. These results are consistent with findings in MDA-MB-231 (transient activation, maximum about  $\times 1.80$ , at 1H).



Fold change measured by the micro-array:  $\times 3.31$  or  $\times 3.04$  (pending on the probe) vs untreated cells.


PTHrP secretion has been known for a long time to be increased by TGF- $\beta$  and to be very important for bone metastasis osteolysis. However, this quantification by real-time PCR could not detect any changes of the transcription induced by TGF- $\beta$ . According to the Ct values observed, PTHrP, among the different genes assessed seems to be one of the most expressed. It is then possible that the transcription can not be further increased. The higher secretion could then be due to a higher stability of the mRNA or to regulation of the translation.

Treatment with actinomycin D after TGF- $\beta$  treatment may then be realized to assess the degradation rate of PTHrP mRNA.



Fold change measured by the micro-array:  $\times 2.93$  vs untreated cells.


No statistically different variations of CTGF mRNA production were detected in PC-3 cells after TGF- $\beta$  treatment. This is quite surprising since CTGF is known to be a target gene of TGF- $\beta$ . We will survey other prostate cancer cells with respect to the effects of TGF- $\beta$  on CTGF transcription.




No changes detected by the micro-array.

TGF- $\beta$  is known to increase IL-6 production in PC-3 cells, based on ELISA assay. However no significant changes of the transcription were observed by qRT-PCR. This increase maybe due to mRNA stabilization or increased translation, as for PTHrP.


**VEGF**  
*VEGF all isoforms*



*VEGF121*



*VEGF165*



Fold change measured by the micro-array:  $\times 2.29$  vs untreated cells.

As opposed to what is suggested by the micro-array, no big increase of VEGF transcription was detected by qRT-PCR in PC-3 cells, after TGF- $\beta$  treatment. However, we know that the VEGF protein secretion is increased by TGF- $\beta$ . It was then possible that only some isoforms of VEGF were affected, we assessed then the effects of TGF- $\beta$  on VEGF121 (or VEGF-F) and VEGF165 (or VEGF-D), expressed in PC-3. However no significant effect of TGF- $\beta$  was observed on these mRNA.

Another assay of VEGF165 mRNA, at 48H, was realized with a higher amount of cDNA as template and showed no effect of TGF- $\beta$  on the transcription of this isoform. Effects of TGF- $\beta$  on VEGF may be due to regulation downstream of the transcription.



## Reportable Outcomes

### Presentations:

- Cancer and Bone. Meet the Professor Session, American Society for Bone and Mineral Research Meeting, Seattle, Washington, September, 2004
- Endothelin A receptor blockade and bisphosphonate therapy in prostate cancer bone metastases. Prostate Cancer Foundation Scientific Retreat (formerly CAPCURE), Lake Tahoe, NV, October, 2004
- Molecular mechanisms of bone metastases. National Cancer Institute, NIH, November, 2004
- TGF $\beta$  blockade in bone metastases. Biogen Advisory Board, Cambridge, MA, December, 2004
- Molecular mechanisms of bone metastases. Endocrinology Grand Rounds, NIH, December, 2004
- Bone metastases: molecular mechanisms and therapeutic interventions. Visiting Professor, Johns Hopkins Cancer Center, February, 2005
- Molecular mechanisms of osteoblastic bone metastases. Orthopaedic Research Society Meeting, Washington DC, February, 2005
- Blockade of TGF $\beta$  signaling in breast cancer metastases to bone. TGF $\beta$  Keystone Meeting, Keystone, CO, March, 2005
- Endothelin-1 in osteoblastic bone metastases: mechanisms and therapeutic implications. Experimental Biology Meeting, San Diego, CA April 2005
- Mechanisms of osteoblastic bone metastases. IVth North American Symposium skeletal complications of malignancy. NIH/NCI, Bethesda, MD, April 2005
- Mechanisms of osteolytic metastases to bone: Implications for therapy. Visiting professor, Fox Chase Cancer Center, Philadelphia, PA, May 2005
- Role of TGF $\beta$  in breast cancer metastases to bone. Seminar, Serono, Boston, MA, May 2005
- Molecular Mechanisms of Osteoblastic Metastases: Implications for therapy. Prostate Cancer: Road Map to the Future. Roswell Park Institute Sponsored Symposium in Niagara Falls NY, July 2005.

### Publications

- Titus B, Frierson HF Jr, Conaway M, Ching K, **Guise T**, Chirgwin J, Hampton G, Theodorescu D. Endothelin Axis Is a Target of the Lung Metastasis Suppressor Gene RhoGDI2. Cancer Res. 2005 65(16):7320-7.
- Clines GA, **Guise TA**. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer. 2005, 12(3):549-83.
- Bendre MS, Margulies AG, Walser B, Akel NS, Bhattacharya S, Skinner RA, Swain F, Ramani V, Mohammad KS, Wessner LL, Martinez A, **Guise TA**, Chirgwin JM, Gaddy D, Suva LJ. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res. 2005 65(23):11001-9.
- Mohammad KS, **Guise TA**. Osteoblastic bone metastases, in Bone Metastases, 1<sup>st</sup> edition. Edited by Keller, Chung. In press 2004
- **Guise TA**, Mohammad KS. Endothelins in bone cancer metastases. Cancer Treat Res. 2004;118:197-212.

- Heras-Herzig A, **Guise TA**. Effects of Drug Treatment for Malignancy on Skeletal Health of Cancer Survivors. Clinical Reviews in Bone and Mineral Metabolism 2(2):103-114, 2004
- Clines GA, Chirgwin JM and **Guise TA**. Skeletal complications of malignancy: Central role for the osteoclast. In: Topics in Bone Biology, Volume 2. Edited by Bronner, Rubin, Farach-Carson. Springer-Verlag, 151-174, 2005.
- Aris RM, **Guise TA**. Cystic fibrosis and bone disease: are we missing a genetic link? Eur Respir J. 2005 25(1):9-11.
- Clines GA, **Guise TA**. Mechanisms and treatment for bone metastases. Clin Adv Hematol Oncol. 2004, 2(5):295-301.
- **Guise TA**. Thromboembolism to Metastasis: The Platelet-Lysophosphatidic Acid Connection IBMS BoneKEy 2005 Mar 1 doi:10.1138/20050154

## Conclusions

A central tenet of the field of bone metastases is that the bone microenvironment supplies factors, such as TGF- $\beta$ , stimulating prostate cancer cell signaling and altering their phenotype. TGF- $\beta$  signaling in cancer is however complex and can lead to the activation of numerous genes. We have identified many of these genes by microarray analysis and have validated the gene reported here. Of these, PMEPA1 as the most highly upregulated gene. We have cloned the PMEPA1 promoter and full-length gene and have begun promoter analysis of the TGF $\beta$  response element. We are in the process of overexpressing PMEPA1 in prostate cancer lines. In vivo experiments are in progress to determine the effect of a TGF $\beta$  RI kinase inhibitor, SD-208, on the development and progression of prostate cancer metastases to bone due to PC-3, LuCAP and C42B prostate cancers.

## References

Abasolo I, Yang L, Haleem R, Xiao W, Pio R, Cuttitta F, Montuenga LM, Kozlowski JM, Calvo A, Wang Z. Overexpression of adrenomedullin gene markedly inhibits proliferation of PC3 prostate cancer cells in vitro and in vivo. *Mol Cell Endocrinol*, 199:179-187, 2003.

Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. *J Urol*, 161:182-187, 1999.

Akhurst RJ, Derynck R. TGF-beta signaling in cancer--a double-edged sword. *Trends Cell Biol*, 11:S44-51, 2001.

Anan T, Nagata Y, Koga H, Honda Y, Yabuki N, Miyamoto C, Kuwano A, Matsuda I, Endo F, Saya H, Nakao M. Human ubiquitin-protein ligase Nedd4: expression, subcellular localization and selective interaction with ubiquitin-conjugating enzymes. *Genes Cells*, 3:751-763, 1998.

Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. *Cancer Res*, 63:1981-1989, 2003a.

Bakin RE, Gioeli D, Bissonette EA, Weber MJ. Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. *Cancer Res*, 63:1975-1980, 2003b.

Bartholin L, Wessner LL, Chirgwin JM, Guise TA. The human Cyr61 gene is a transcriptional target of transforming growth factor beta in cancer cells. *Cancer Lett*. 2006

Bello-DeOcampo D, Tindall DJ. TGF-beta1/Smad signaling in prostate cancer. *Curr Drug Targets*, 4:197-207. 2003.

Bendre MS, Gaddy-Kurten D, Mon-Foote T, Akel NS, Skinner RA, Nicholas RW, Suva LJ. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. *Cancer Res*, 62:5571-5579, 2002.

Blackledge G. Growth Factor Receptor Tyrosine Kinase Inhibitors; Clinical Development and Potential for Prostate Cancer Therapy. *J Urol*, 170:S77-S83, 2003.

Blanchere M, Saunier E, Mestayer C, Broshuis M, Mowszowicz I. Alterations of expression and regulation of transforming growth factor beta in human cancer prostate cell lines. *J Steroid Biochem Mol Biol*, 82:297-304, 2002.

Boyde A, Maconnachie E, Reid SA, Delling G, Mundy GR. Scanning electron microscopy in bone pathology: Review of methods. Potential and applications. *Scanning Electron Microscopy IV*:1537-1554, 1986.

Brigstock DR. Regulation of angiogenesis and endothelial cell function by connective tissue growth factor (CTGF) and cysteine-rich 61 (CYR61). *Angiogenesis*, 5:153-165, 2002.

Brunschwig EB, Wilson K, Mack D, Dawson D, Lawrence E, Willson JK, Lu S, Nosrati A, Rerko RM, Swinler S, Beard L, Lutterbaugh JD, Willis J, Platzer P, Markowitz S. PMEPA1, a transforming growth factor-beta-induced marker of terminal colonocyte differentiation whose expression is maintained in primary and metastatic colon cancer. *Cancer Res*, 63:1568-1575, 2003.

Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. *J Clin Oncol*, 21:679-689, 2003.

Cher ML. Mechanisms governing bone metastasis in prostate cancer. *Curr Opin Urol*, 11:483-488, 2001.

Chesneau V, Becherer JD, Zheng Y, Erdjument-Bromage H, Tempst P, Blobel CP. Catalytic properties of ADAM19. *J Biol Chem*, 278:22331-22340, 2003.

Chipuk JE, Cornelius SC, Pultz NJ, Jorgensen JS, Bonham MJ, Kim SJ, Danielpour D. The androgen receptor represses transforming growth factor-beta signaling through interaction with Smad3. *J Biol Chem*, 277:1240-1248, 2002.

Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. *Crit Rev Eukaryot Gene Expr*, 10:159-178, 2000.

Chirgwin JM, Guise TA. Molecular mechanisms of cancer metastases to bone. *Curr Opin Orthop*, 14:317-321, 2003a.

Chirgwin JM, Guise TA. Cancer metastasis to bone. *Science & Medicine*, 9:140-151, 2003b.

Chung LW. Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications. *Cancer*, 97(3 Suppl):772-778, 2003.

Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. *Prostate*, 52:20-33, 2002.

- Crawford ED. Epidemiology of prostate cancer. *Urology*, 62(6 Suppl 1):3-12, 2003.
- Crawford *et al.* 1998. *Cell*. 93:1159
- Good *et al.* 1990. *PNAS*. 87:6624
- Volpert *et al.* 1998. *PNAS*. 95:6343
- Filleur *et al.* 2001. *Genes & Dev*. 15:1373
- Fontana *et al.* 2005. *Int. J. Cancer*. 116:686
- Dallas SL, Rosser JL, Mundy GR, Bonewald LF. Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. *J Biol Chem*, 277:21352-21360, 2002.
- Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. *Nature*, 425:577-584, 2003.
- Deftos LJ. Prostate carcinoma: production of bioactive factors. *Cancer*, 88(12 Suppl):3002-3008, 2000.
- Feng XH, Liang YY, Liang M, Zhai W, Lin X. Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B). *Mol Cell*, 9:133-143, 2002.
- Festuccia C, Angelucci A, Gravina GL, Villanova I, Teti A, Albini A, Bologna M, Abini A. Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells. *Int J Cancer*, 85:407-415, 2000.
- Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. *Nat Rev Cancer*, 3:1-6, 2003.
- Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, Keller ET. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. *J Natl Cancer Inst*, 95:878-889, 2003a.
- Fu Y, O'Connor LM, Shepherd TG, Nachtigal MW. The p38 MAPK inhibitor, PD169316, inhibits transforming growth factor beta-induced Smad signaling in human ovarian cancer cells. *Biochem Biophys Res Commun*, 310:391-397, 2003b.
- Gallwitz WE, Guise TA, Mundy GR. Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. *J Clin Invest*, 110:1559-1572, 2002.
- Giannini G, Ambrosini MI, Di Marcotullio L, Cerignoli F, Zani M, MacKay AR, Screpanti I, Frati L, Gulino A. EGF- and cell-cycle-regulated STAG1/PMEPA1/ERG1.2

belongs to a conserved gene family and is overexpressed and amplified in breast and ovarian cancer. *Mol Carcinog*, 8:188-200, 2003.

Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. *Cancer Res*, 59:279-284, 1999.

Gioeli D, Zecevic M, Weber MJ. Immunostaining for activated extracellular signal-regulated kinases in cells and tissues. *Methods Enzymol*, 332:343-353, 2001.

Granchi S, Brocchi S, Bonaccorsi L, Baldi E, Vinci MC, Forti G, Serio M, Maggi M. Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. *Prostate*, 49:267-277, 2001.

Grotendorst GR, Okochi H, Hayashi N. A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene. *Cell Growth Differ*, 7:469-480, 1996.

Guisse TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. *J Clin Invest*, 98:1544-1549, 1996.

Guisse TA, Mundy GR. Cancer and bone. *Endocr Rev*, 19:18-55, 1998.

Guisse TA, Chirgwin JM. Role of bisphosphonates in prostate cancer bone metastases. *Semin Oncol*, 30:717-723, 2003a.

Guisse TA, Chirgwin JM. Transforming growth factor-beta in osteolytic breast cancer bone metastases. *Clin Orthop*, 415:S32-38, 2003b.

Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. *J Biol Chem*, 261:12665-12674, 1986.

Hayes SA, Huang X, Kambhampati S, Platanias LC, Bergan RC. p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion. *Oncogene*, 22:4841-4850, 2003.

Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. *N Engl J Med*, 335: 1785-1791, 1996.

Hwa V, Oh Y, Rosenfeld RG. Insulin-like growth factor binding protein-3 and -5 are regulated by transforming growth factor-beta and retinoic acid in the human prostate adenocarcinoma cell line PC-3. *Endocrine*, 6:235-242, 1997.

Itoh S, Thorikay M, Kowanetz M, Moustakas A, Itoh F, Heldin CH, ten Dijke P. Elucidation of Smad requirement in transforming growth factor-beta type I receptor-induced responses. *J Biol Chem*, 278:3751-3761, 2003.

Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, Beug H, Grunert S. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. *J Cell Biol*, 156:299-313, 2002.

Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. *Science*, 298:1911-1912, 2002.

Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, Grubbs BG, Dallas M, Cui Y, Guise TA. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. *J Biol Chem*, 277:24571-24578, 2002.

Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J. A multigenic program mediating breast cancer metastasis to bone. *Cancer Cell*, 3:537-549, 2003.

Keller ET. The role of osteoclastic activity in prostate cancer skeletal metastases. *Drugs Today*, 38:91-102, 2002.

Kozawa O, Kawamura H, Hatakeyama D, Matsuno H, Uematsu T. Endothelin-1 induces vascular endothelial growth factor synthesis in osteoblasts: involvement of p38 mitogen-activated protein kinase. *Cell Signal*, 12:375-380, 2000.

Liao Y, Hung MC. Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis. *Mol Cell Biol*, 23:6836-6848, 2003.

Lum *et al.* 1999. *JBC*. 274:13613

Lynch CC, Hikosaka A, Acuff HB, Martin MD, Kawai N, Singh RK, Vargo-Gogola TC, Begtrup JL, Peterson TE, Fingleton B, Shirai T, Matrisian LM, Futakuchi M. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. *Cancer Cell*. 2005 May;7(5):485-96.

Mackie EJ, Ramsey S. Modulation of osteoblast behaviour by tenascin. *J Cell Sci*, 109:1597-1604, 1996.

Mackie EJ, Abraham LA, Taylor SL, Tucker RP, Murphy LI. Regulation of tenascin-C expression in bone cells by transforming growth factor-beta. *Bone*, 22:301-307, 1998.



Maeda S, Hayashi M, Komiya S, Imamura T, Miyazono K. Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells. *EMBO J*. 2004 Jan 29 [Epub ahead of print]

Merrell M, Suarez-Cuervo C, Harris KW, Vaananen HK, Selander KS. Bisphosphonate induced growth inhibition of breast cancer cells is augmented by p38 inhibition. *Breast Cancer Res Treat*, 81:231-241, 2003.

Miyake H, Pollak M, Gleave ME. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. *Cancer Res*, 60:3058-3064, 2000.

Mohammad KS, Guise TA. Mechanisms of osteoblastic metastases: role of endothelin-1. *Clin Orthop*, 415:S67-74, 2003.

Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. *Nat Rev Cancer*, 2:584-593, 2002.

Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. *J Clin Invest*, 109:1551-1559, 2002.

Nelson JB. Endothelin Inhibition: Novel Therapy for Prostate Cancer. *J Urol*, 170:S65-S68, 2003.

O'Keefe RJ, Guise TA. Molecular mechanisms of bone metastasis and therapeutic implications. *Clin Orthop*, 415(Suppl):S100-104, 2003.

Park BJ, Park JI, Byun DS, Park JH, Chi SG. Oncogenic conversion of transforming growth factor-beta1 effect by oncogenic Ha-Ras-induced activation of the mitogen-activated protein kinase signaling pathway in human prostate cancer. *Cancer Res*, 60:3031-3038, 2000.

Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS, Ryu BK, Park YK, Chi SG. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. *Oncogene*, 22:4314-4332, 2003.

Pfitzenmaier J, Quinn JE, Odman AM, Zhang J, Keller ET, Vessella RL, Corey E. Characterization of C4-2 prostate cancer bone metastases and their response to castration. *J Bone Miner Res*, 18:1882-1888, 2003.

Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. *Prostate*, 44:77-87, 2000.

Rae FK, Hooper JD, Nicol DL, Clements JA. Characterization of a novel gene, STAG1/PMEPA1, upregulated in renal cell carcinoma and other solid tumors. *Mol Carcinog*, 32:44-53, 2001.

Reddi AH, Roodman D, Freeman C, Mohla S: Mechanisms of tumor metastasis to the bone: challenges and opportunities. *J Bone Miner Res*, 18:190-194, 2003

Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. *Proc Natl Acad Sci USA*, 100:8621-8623, 2003.

Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. *Cancer Res*, 63:5978-5991, 2003.

Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. *J Natl Cancer Inst*, 94:1458-68, 2002.

Safadi FF, Xu J, Smock SL, Kanaan RA, Selim AH, Odgren PR, Marks SC Jr, Owen TA, Popoff SN.

Expression of connective tissue growth factor in bone: its role in osteoblast proliferation and differentiation in vitro and bone formation in vivo. *J Cell Physiol*, 196:51-62, 2003.

Shah AH, Tabayoyong WB, Kundu SD, Kim SJ, Van Parijs L, Liu VC, Kwon E, Greenberg NM, Lee C. Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice. *Cancer Res*, 62:7135-7138, 2002.

Schultz RM. Potential of p38 MAP kinase inhibitors in the treatment of cancer. *Prog Drug Res*, 60:59-92, 2003.

Shariat SF, Shalev M, Menesses-Diaz A, Kim IY, Kattan MW, Wheeler TM, Slawin KM. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. *J Clin Oncol*, 19:2856-2864, 2001.

Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. *Proc Natl Acad Sci USA*, 100:8430-8435, 2003.

Street J, Bao M, deGuzman L, Bunting S, Peale FV Jr, Ferrara N, Steinmetz H, Hoeffel J, Cleland JL, Daugherty A, van Bruggen N, Redmond HP, Carano RA, Filvaroff EH. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. *Proc Natl Acad Sci U S A*. 2002 Jul 23;99(15):9656-61

Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, Wakefield LM. TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. *J Clin Invest*, 112:1116-1124, 2003.

Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. *Cancer Res*, 54:2577-2581, 1995.

Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ, Gillespie MT. Breast cancer cells interact with osteoblasts to support osteoclast formation. *Endocrinol*, 140:4451-4458, 1999.

Tokuda H, Hatakeyama D, Akamatsu S, Tanabe K, Yoshida M, Shibata T, Kozawa O. Involvement of MAP kinases in TGF-beta-stimulated vascular endothelial growth factor synthesis in osteoblasts. *Arch Biochem Biophys*, 415:117-125, 2003.

Tuxhorn JA, McAlhany SJ, Yang F, Dang TD, Rowley DR. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. *Cancer Res*, 62:6021-6025, 2002.

Uy HL, Mundy GR, Boyce BF, Story BM, Dunstan CR, Yin JJ, Roodman GD, Guise TA. Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. *Cancer Res*, 57:3194-3199, 1997.

van der Pluijm G, Sijmons B, Vloedgraven H, Deckers M, Papapoulos S, Lowik C. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. *J Bone Miner Res*, 16:1077-1091, 2001.

Wikstrom P, Damber J, Bergh A. Role of transforming growth factor-beta1 in prostate cancer. *Microsc Res Tech*, 52:411-419, 2001.

Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, Yang H, Zhau HE, Balian G, Chung LW. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. *Int J Cancer*, 77:887-894, 1998.

Xu LL, Shanmugam N, Segawa T, Sesterhenn IA, McLeod DG, Moul JW, Srivastava S. A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate. *Genomics*, 66:257-263, 2000.

Xu LL, Shi Y, Petrovics G, Sun C, Makarem M, Zhang W, Sesterhenn IA, McLeod DG, Sun L, Moul JW, Srivastava S. PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression. *Cancer Res*, 63:4299-4304, 2003.

Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, MacGregor J, Patel SC, Khozin S, Liu ZY, Green J, Anver MR, Merlino G, Wakefield LM. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. *J Clin Invest*, 109:1607-1615, 2002.

Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massague J, Mundy GR, Guise TA. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. *J Clin Invest*, 103:197-206, 1999.

Yin JJ, Mohammad KS, Kakonen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, Guise TA. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. *Proc Natl Acad Sci USA*, 100:10954-10959, 2003

Yoneda T, Sasaki A, Dunstan C, Williams PJ, Bauss F, De Clerck YA, Mundy GR. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. *J Clin Invest*, 99:2509-2517, 1997.

Zheng *et al.* 2004. *JBC*. 279:42898

Zhou W, Park I, Pins M, Kozlowski JM, Jovanovic B, Zhang J, Lee C, Illo K. Dual regulation of proliferation and growth arrest in prostatic stromal cells by transforming growth factor-beta1. *Endocrinology*, 144:4280-4284, 2003.